Partial response (>33% improvement) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in partial response (>33% improvement) compared with placebo; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Confirmed symptomatic COVID‐19b
1 finding from 1 review
Severe or critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systemic reactogenicity events
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in systemic reactogenicity eventse compared with placebo (moderate certainty).
1 finding from 1 review
Any adverse eventh
1 finding from 1 review
Serious adverse eventsk
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Local reactogenicity events
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to lower pain (mean score) compared with topical curcumin (low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean score) compared with intralesional BCG-polysaccharide nucleic acid (BCG-PSN); GRADE not reported.
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide may leads to higher clinical score compared with photodynamic therapy (low certainty).
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes clinical resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse effects compared with topical ciclosporin; GRADE not reported.
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide showed no clear difference in pain (mean score) compared with hyaluronic acid gel; GRADE not reported.
1 finding from 1 review
Pain (mean score, split-mouth) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical triamcinolone acetonide changes pain (mean score, split-mouth) compared with cryotherapy (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
The review found no eligible studies for this question.
1 finding from 1 review